�Submission Based on Phase III Study Showing Superior Results
for MabThera in Chronic Lymphocytic Leukaemia (CLL) When Added to
Standard Chemotherapy
Today, Roche submitted a Marketing Authorisation Application (MAA) to the
European Medicines Agency (EMEA) for the
